Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Jacobson PharmaHKSE:02633 -0.96%56 Operating Margin % is 23.52% as of Mar. 2026, which is 24% above its 10-year median of 18.98. GuruFocus rates HKSE:02633 with a GF Score™ of 56/100 and a GF Value™ of HK$0.85 (Modestly Overvalued). The stock has 2 warning signs investors should review. Among 959 Drug Manufacturers companies, Jacobson Pharma ranks better than 87.28% on this metric.
Jacobson Pharma Corp Ltd operating margin is expanding. Margin expansion is usually a good sign.
The historical rank and industry rank for Jacobson Pharma's Operating Margin % or its related term are showing as below:
HKSE:02633'
s Operating Margin % Range Over the Past 10 Years
Min: 13.81 Med: 18.98 Max: 23.4
Current: 22.79
HKSE:02633's Operating Margin % is ranked better than 87.28% of 959
companies
in the Drug Manufacturers industry
Industry Median: 7.31
vs HKSE:02633: 22.79
Jacobson Pharma's 5-Year Average Operating Margin % Growth Rate was 9.60% per year.
Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.
Be Aware
Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).
If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.
For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokias Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).
Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.
Jacobson Pharma Operating Margin % Related Terms
Jacobson Pharma Operating Margin % Historical Data
* Premium members only.
The historical data trend for Jacobson Pharma's Operating Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Jacobson Pharma's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Jacobson Pharma Operating Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Jacobson Pharma's Operating Margin % distribution charts can be found below:
* The bar in red indicates where Jacobson Pharma's Operating Margin % falls into.
Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.
Jacobson Pharma's Operating Margin % for the fiscal year that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Jacobson Pharma (HKSE:02633) has a Operating Margin % of 23.52% as of Mar. 2026. Operating margin is the ratio of total operating income to net sales. View historical data on Jacobson Pharma and its competitors. This is 24% above median its historical median of 18.98. Over the past decade, Jacobson Pharma's Operating Margin % has ranged from 13.81 to 23.40. According to the industry distribution chart, Jacobson Pharma ranks #122 out of 959 companies in the Drug Manufacturers industry, placing it in the top 12.7%.
Is Jacobson Pharma's Operating Margin % too high?
Jacobson Pharma's current Operating Margin % of 23.52% is 24% above median its 10-year median of 18.98. Over the past 10 years, this metric has ranged from a low of 13.81 to a high of 23.40. The Drug Manufacturers industry median Operating Margin % is 7.31. Jacobson Pharma's value of 23.52% is 221.8% above this industry median. Based on the distribution chart, Jacobson Pharma ranks #122 out of 959 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Jacobson Pharma has a GF Score™ of 56/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Jacobson Pharma's Operating Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Jacobson Pharma ranks #122 out of 959 companies for Operating Margin %. This places Jacobson Pharma in the top 13% of its industry — outperforming the majority of peers. The industry median Operating Margin % is 7.31. Jacobson Pharma's value of 23.52% is 221.8% above this benchmark. Historically, Jacobson Pharma's own Operating Margin % has ranged from 13.81 to 23.40 over the past decade. While the company's 10-year median is 18.98 vs. the industry median of 7.31, Jacobson Pharma has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Operating Margin % for a Drug Manufacturers company?
The median Operating Margin % among Drug Manufacturers companies is 7.31, based on 959 companies in the industry. Companies in the top quartile (top 25%) have a Operating Margin % significantly above this median, while those in the bottom quartile fall well below. However, Operating Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Jacobson Pharma's current Operating Margin % of 23.52% is 221.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Operating Margin % mean?
A high Operating Margin % can signal that a stock is expensive relative to its fundamentals. Operating margin is the ratio of total operating income to net sales. View historical data on Jacobson Pharma and its competitors. For the Drug Manufacturers industry, the median Operating Margin % is 7.31 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Jacobson Pharma's current Operating Margin % is 23.52%, which is 24% above median its own 10-year median of 18.98. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Jacobson Pharma stock overvalued right now?
Based on GuruFocus' analysis, Jacobson Pharma (HKSE:02633) is currently considered Modestly Overvalued. The stock's GF Value™ is HK$0.85, compared to a current price of HK$1.04 — trading 21.8% above its estimated fair value. The current Operating Margin % is 23.52%, which is 24% above median its 10-year median of 18.98 and 221.8% above the Drug Manufacturers industry median of 7.31. Jacobson Pharma's overall GF Score™ is 56/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Operating Margin % calculated?
Operating Margin % is calculated from a company's financial statements. For Jacobson Pharma (HKSE:02633), the current Operating Margin % is 23.52% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Jacobson Pharma (HKSE:02633) Overvalued in 2026?
Based on GuruFocus' analysis, Jacobson Pharma stock appears to be overvalued.
The current stock price of HK$1.04 is trading 21.8% above its estimated GF Value™ of HK$0.85.
GuruFocus considers Jacobson Pharma to be Modestly Overvalued.
Key valuation signals for HKSE:02633:
Operating Margin %: 23.52% (24% above median its 10-year median of 18.98)
GF Value™: HK$0.85 vs. price of HK$1.04 (21.8% above fair value)
Industry Position: 221.8% above the Drug Manufacturers median (#122 of 959)
No single metric tells the full story. See the HKSE:02633 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Jacobson Pharma Corp Ltd is an investment holding company. It is principally engaged in the development, production, marketing, and sale of generic drugs. The company's operating segment includes Generic drugs; Branded healthcare, Wholesale, and retail The generic drugs segment develops, manufactures, and distributes a host of off-patent medicines for various therapeutic use. It generates maximum revenue from the Generic drugs segment. Geographically, it derives a majority of its revenue from Hong Kong and also has a presence in Mainland China, Macau, Singapore, and Other Countries.
56GF Score
Get the complete analysis for HKSE:02633
Operating Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:02633 has been successfully added to your 
